Pretty lately, preliminary benefits from a 3rd demo evaluating ibrutinib vs . observation were presented.a hundred and five Clients receiving ibrutinib had a longer event-cost-free survival, but no overall survival edge, Even though the final results were nonetheless immature. Also, although significant adverse situations prices have been comparabl